Sanofi Abandons Phase 3 Trial of Neurology Drug Riliprubart

Why It Matters

The trial’s failure narrows Sanofi’s near‑term growth prospects in the niche CIDP market and underscores the challenge of translating complement inhibition into clinical benefit. Competitors may capture market share as Sanofi reallocates resources to later‑stage programs.

Key Takeaways

• MOBILIZE trial stopped early due to futility
• ~140 CIDP patients enrolled, all refractory to standard care
• VITALIZE trial continues, results due next year
• Sanofi’s C1s focus includes Enjaymo and transplant study
• Bioverativ acquisition cost $11.6 billion in 2018

Pulse Analysis

Sanofi’s decision to abandon the MOBILIZE phase 3 trial highlights the volatility of the neurology pipeline, especially for rare autoimmune disorders like chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP affects roughly 8 per 100,000 people, causing progressive weakness and disability that often requires intravenous immune globulin (IVIg) or corticosteroids. Sanofi’s riliprubart, a C1s‑targeting antibody, was designed to modulate the classical complement pathway, a mechanism also leveraged in its approved CAD therapy Enjaymo. The early termination after an interim futility analysis signals that the drug’s pharmacologic impact may not translate into meaningful clinical improvement for patients who have already failed existing treatments.

The trial’s outcome reverberates across the specialty‑neurology market, where few disease‑modifying options exist beyond IVIg and newer agents like Argenx’s Vyvgart Hytrulo. By pulling the plug on MOBILIZE, Sanofi forfeits a potential revenue stream estimated in the low‑hundreds of millions if the drug had succeeded, while opening space for competitors to solidify their foothold. Investors will watch the parallel VITALIZE study closely; a positive interim signal could partially offset the setback, but the risk remains high given the stringent efficacy benchmarks in CIDP trials. The failure also prompts a reassessment of Sanofi’s allocation of R&D capital, potentially shifting focus toward later‑stage assets or alternative complement targets.

Looking ahead, Sanofi’s C1s portfolio is not dead. A phase 2 trial in antibody‑mediated transplant rejection continues, and the company’s broader complement‑inhibition strategy may benefit from emerging data on related molecules such as Dianthius Therapeutics’ claseprubart. The industry’s interest in complement pathways suggests that, despite this setback, the scientific premise remains attractive. Sanofi’s ability to leverage its Bioverativ acquisition—originally a $11.6 billion investment—to accelerate other hematology and immunology programs will be critical in maintaining its competitive edge in the evolving biotech landscape.